

Supplemental Table 1. Clinical Characteristics and Clinical Course

Patient	1	2	3	4	5	6	7	8	9	10	Total (n=10)
Age (yr)	70	72	39	75	67	54	49	62	43	54	58 (49-70)
Gender (male)	Male	Male	Male	Male	Male	Male	Male	Female	Male	Female	8 (80%)
Chronic Conditions	CAD, HTN, DM, Morbid Obesity	HTN	Smoker, Psoriasis, IC, Obesity	DM, HTN	CAD, Heart Failure	Obesity	Morbid Obesity	HTN	Morbid Obesity	DM, Morbid Obesity	N/A
BMI	36	30	35	21	34	35	70	29	41	39	35 (30-39)
Days from symptom onset-ICU admission	9	10	16	6	12	7	14	12	7	12	11 (7-12)
SOFA score	2	4	5	4	3	3	8	4	5	5	4 (3-5)
P/F ratio, ICU admission	213	139	204	268	189	150	64	138	192	113	169.5 (138-204)
Platelet Count (per mm ³)	298	502	273	176	384	481	377	241	83	285	291 (224-408)
C-Reactive Protein (mg/L)	12.5	25.1	31.3	5.1	16.2	24.6	25.3	28.9	14.3	10.1	20.4 (12.5-25.3)
Serum Ferritin (ng/mL)	1,796	4,749	3,368	2,919	350	4,981	2,911	1,796	7,518	881	2915 (1796-4749)
D-Dimer (mcg/mL)	1	4.5	13.1	3.9	0.9	14.1	2.4	1	1.8	6.62	3.15 (1-6.62)
Creatine Kinase (u/L)	31	106	26	977	69	230	10,835	34	168	39	87.5 (34-230)
Fibrinogen (mg/dL)	543	>1000	N/A	N/A	N/A	530	769	676	N/A	N/A	676 (543-769)
Lactate Dehydrogenase (U/L)	349	359	741	400	446	898	679	490	538	330	468 (359-679)
FiO ₂ (%)	40	45	80	35	40	40	100	70	50	60	48 (40-70)
PEEP (cm H ₂ O)	14	7	14	8	8	10	20	14	16	14	14 (8-15)
Ventilatory Ratio	1.68	2.26	1.9	1.1	1.3	2.02	2.61	1.19	1.6	1.81	1.75 (1.27-2.08)
Ventilator Mode	VC	PRVC	PRVC	PRVC	PRVC	VC	VC	VC	PRVC	VC	
Plateau Pressure (cm H ₂ O)	20	N/A	26	17	N/A	20	33	23	30	19	22 (19-29)
Ventilator Days	2	13	7	21	8	8	3	15	19	7	8 (3-8)
Prone positioning	No	No	No	No	No	No	No	No	No	No	0
Paralytics	No	No	Yes	No	No	No	Yes	Yes	Yes	No	4 (40%)
Vasopressor Support	No	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	6 (60%)
Extrapulmonary Organ Failure	No	No	AKI	No	No	AKI, CHF	AKI	No	No	AKI	4 (40%)
Renal Replacement Therapy	No	No	Yes	No	No	Yes	Yes	No	No	No	3 (30%)
Medical Therapy	CQ, Tocilizumab	CQ	CQ, Alteplase, Steroids	CQ	CQ	CQ, Steroids	CQ, iNO, Steroids, Alteplase	iNO, Steroids	CQ, Steroids, Alteplase	CQ, Steroids, Alteplase	N/A
ICU Length of Stay	4	15	11	22	12	8	3	18	23	10	11.5 (7-19)
Hospital Length of Stay	12	18	20	NR	24	8	3	28	NR	14	16 (9-23)
Outcome	Alive	Alive	Alive	Alive	Alive	Dead	Dead	Alive	Alive	Alive	2 (20%)

Table 1: Clinical Characteristics and Clinical Course. Demographic, laboratory and ventilatory data for patients with COVID-19-associated respiratory failure evaluated with TEG. AKI: Acute Kidney Injury, CAD: Coronary Artery Disease, CQ: Chloroquine, HTN: Hypertension, DM: Diabetes Mellitus, IC: Immunocompromised, iNO: Inhaled Nitric Oxide. Totals given as n (percentage) or median (interquartile range); NR = not reached/ongoing